Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Potassium two pore domain channel subfamily K member 9 (KCNK9, also known as TASK3) is a pH-sensitive, two-pore domain potassium ion channel that contributes to “leak” potassium currents, helping to set membrane potential and regulate cellular excitability, especially in neurons. It is expressed most highly in the brain (notably cerebellum and hippocampus) but is present in various tissues including the adrenal gland and retina. KCNK9 is regulated by extracellular pH and signaling pathways involving G protein-coupled receptors, and is inhibited by various endogenous and pharmacologic molecules. Overexpression or amplification of KCNK9 has been identified in multiple human cancers, where it promotes proliferation and resistance to apoptosis, illustrating both physiological and pathological roles. Genetic variants of KCNK9 cause congenital imprinting syndromes. There are currently no approved drugs that specifically target KCNK9 clinically, but its modulation is a subject of active research for both neurologic and oncologic indications
Opening or closing the channel regulates potassium (K+) outflow, affecting membrane potential and cell excitability. Inhibition results in depolarization, altering neuronal signaling, hormone release, and potentially promoting or inhibiting tumorigenic processes. In oncogenesis, overexpression increases resistance to apoptosis and cell proliferation via alteration of membrane potential and downstream signaling pathways.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Potassium two pore domain channel subfamily K member 9 (KCNK9).